Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion.
J Cereb Blood Flow Metab
; 28(3): 482-9, 2008 Mar.
Article
en En
| MEDLINE
| ID: mdl-17684515
ABSTRACT
An adjuvant therapy to prolong the therapeutic window for stroke patients is urgently needed. This randomized, blinded, placebo-controlled study investigated adjuvant intravenous sodium nitrite with recombinant tissue plasminogen activator (rtPA) in middle cerebral artery occlusion (MCAO) with 6 and 2 h of ischemia followed by reperfusion in Sprague-Dawley rats (n=59). Quantitative diffusion, T(1)-, T(2)-weighted, and semiquantitative perfusion imaging were performed before and after reperfusion and at 48 h after ischemia to determine the spatiotemporal evolution of stroke. After 48 h animals were killed and examined to evaluate infarct size and evidence of hemorrhagic transformation. Factor VIII immunostaining was performed to assess vessel morphology. Nitrite treatment (6 h group 37.5 micromol for more than 90 mins; 2 h group 26.25 and 1.75 micromol for more than 60 mins) did not reduce infarct volume 48 h after MCAO compared with saline-treated placebo groups after 6 or 2 h of MCAO. Stroke progression from baseline to 48 h, based on the apparent diffusion coefficient and relative cerebral blood flow deficits before and after reperfusion and T(2)-weighted hyperintensity at 48 h, did not differ between treated and control animals. These results suggest that nitrite is not a protective adjuvant therapy to delayed rtPA administration after ischemic stroke in rats.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Daño por Reperfusión
/
Terapia Trombolítica
/
Accidente Cerebrovascular
/
Nitritos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Cereb Blood Flow Metab
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos